Role of primary miRNA polymorphic variants in metastatic colon cancer patients treated with 5-fluorouracil and irinotecan
Open Access
- 29 June 2010
- journal article
- Published by Springer Nature in The Pharmacogenomics Journal
- Vol. 11 (6) , 429-436
Abstract
MicroRNAs are non-coding RNAs that can block mRNA translation and influence mRNA stability. Recent evidence indicates that miRNA variations can affect drug resistance, efficacy, and metabolism, opening new avenues of pharmacogenomics research. We investigated associations between polymorphisms in both miRNA-containing genomic regions (primary and precursor miRNA) and in genes related to miRNA biogenesis with clinical outcome in metastatic colorectal cancer (mCRC) patients treated with 5-fluorouracil and irinotecan (CPT-11). Eighteen single-nucleotide polymorphisms (SNPs) were analyzed in 61 patients. A significant association with tumor response and time to progression (TTP) was found for SNP rs7372209 in pri-miR26a-1 (P=0.041 and P=0.017, respectively). The genotypes CC and CT were favorable when compared with the TT variant genotype. In addition, SNP rs1834306, located in the pri-miR-100 gene, significantly correlated with a longer TTP (P=0.04). In the miRNA-biogenesis pathway, a trend was identified between SNP rs11077 in the exportin-5 gene and disease control rate (P=0.076). This study is the first to suggest a relationship between treatment outcome and SNPs in the miRNA-biogenesis machinery, in both primary and precursor miRNAs. Our results suggest that miRNA polymorphic variants might be useful predictors of clinical outcome in mCRC patients treated with 5-fluorouracil and CPT-11 combination.Keywords
This publication has 46 references indexed in Scilit:
- microRNA-451 Regulates Macrophage Migration Inhibitory Factor Production and Proliferation of Gastrointestinal Cancer CellsClinical Cancer Research, 2009
- MicroRNA Polymorphisms: the Future of Pharmacogenomics, Molecular Epidemiology and Individualized MedicinePharmacogenomics, 2009
- The impact of microRNAs and alternative splicing in pharmacogenomicsThe Pharmacogenomics Journal, 2009
- miR-192 Regulates Dihydrofolate Reductase and Cellular Proliferation through the p53-microRNA CircuitClinical Cancer Research, 2008
- Single nucleotide polymorphism associated with mature miR-125a alters the processing of pri-miRNAHuman Molecular Genetics, 2007
- Human polymorphism at microRNAs and microRNA target sitesProceedings of the National Academy of Sciences, 2007
- Involvement of Human Micro-RNA in Growth and Response to Chemotherapy in Human Cholangiocarcinoma Cell LinesGastroenterology, 2006
- MicroRNA Gene Expression Deregulation in Human Breast CancerCancer Research, 2005
- Polymorphisms in human pre-miRNAsBiochemical and Biophysical Research Communications, 2005
- Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemiaProceedings of the National Academy of Sciences, 2002